Biopharmaceutical company Covistat said on Thursday that it is one step closer in developing the low cost treatment nafamostat for COVID-19 via the acquisition of the technology and intellectual property of Mucokinetica.
In the fight against COVID-19, Dr Peter Cole and Dr Rod Hall, founders of Mucokinetica Ltd and world-leading experts in respiratory diseases and cystic fibrosis, are joining the Covistat team. Mucokinetica's technology and intellectual property will accelerate the efforts to develop a low-cost treatment that helps the body's ability to block the coronavirus and its mutating variations from infiltrating our cells.
The companies added that nafamostat blocks TMPRSS2, the enzyme that enables SARS-CoV-2's spike proteins to gain entry into cells. Whether suffering from mild symptoms at home or acute respiratory failure in a hospital, nafamostat's therapy is expected to reduce the viral load in patients and prevent the progression of COVID-19.
Additionally, Covistat is working to repurpose this proven generic drug nafamostat into oral, intranasal and inhaled therapies for COVID-19 patients, including those in remote and developing regions of the world.
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant
Insmed completes adult patient enrolment in brensocatib pivotal ASPEN study
Aluna Raises USD 15.3m in Series B Funding
CF Foundation Invests Up to USD 15m in ReCode Therapeutics for Development of mRNA Therapy
Markels Named to Arcturus Therapeutics Board of Directors
SpliSense commences first-in-human, Phase 1/2 clinical trial of SPL84 to treat cystic fibrosis
Arcturus Forges Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Vanda Pharmaceuticals VPO-227 granted US FDA Orphan Drug Designation for the treatment of cholera